Posted inUncategorized
Scotland leads the UK in approving injectable HIV PrEP
The Scottish Medicines Consortium (SMC) has approved CAB-LA, an injection taken every two months, for…
Gilead to support generic lenacapavir in low-income nations
Earlier this month, Gilead Sciences announced that it had signed non-exclusive, royalty-free voluntary licensing agreements…
Posted inCampaigning International News Prevention
Activists demand global access to HIV prevention drug
HIV and sexual health activists protested today at Gilead Sciences' London Office demanding the company…
Posted inNews PrEP Prevention Research
Twice-yearly lenacapavir 89% more effective than Truvada
New data from the PURPOSE 2 study shows that twice-yearly lenacapavir is 89% more effective…
Posted inInternational News PrEP Prevention
Concern as PrEP supplies run low in Australia
Australian sexual health and HIV organisations are sending out reminders for PrEP users to "plan…
Posted inHealthcare International News PrEP Prevention
PrEP approved to prevent HIV in Japan
Japan has approved the use of Truvada (TDF/FTC), sold by Gilead Sciences under the brand name Truvada, as PrEP for the prevention of HIV in the country.
Posted inNews PrEP Prevention
UK’s first Digital PrEP service starts in East Sussex
A new digital PrEP service has just launched in East Sussex, making it easier for…
Posted inHealthcare Medicines News Parenting PrEP Prevention Research
Cabotegravir PrEP injection is safe during pregnancy
The safety and tolerability of long-acting injectable cabotegravir (CAB-LA) as HIV pre-exposure prophylaxis (PrEP) for…
Posted inConferences Healthcare Medicines News PrEP Prevention
Twice-yearly lenacapavir injection sees zero HIV infections in trial
AIDS 2024 Conference Coverage Preliminary findings from the phase III PURPOSE 1 trial revealed that…